Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-06-25
1997-10-14
Jagannathan, Vasu S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3900
Patent
active
056772742
ABSTRACT:
The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided. The steps of the method include a) administering to the cell a protein comprising the translocation domain and the LF binding domain of the native PA protein and a ligand domain, and b) administering to the cell a product comprising the PA binding domain of the native LF protein and a non-LF activity inducing moiety, whereby the product administered in step b) is internalized into the cell and performs the activity within the cell. The invention also provides proteins including an anthrax protective antigen which has been mutated to replace the trypsin cleavage site with residues recognized specifically by the HIV-1 protease.
REFERENCES:
Klimpel et al, "Modified Anthrax Toxin is Cleaved . . . by HIV-1 Protease" J. Cell. Biochem, Suppl. 18B:163, abstract J515 (Jan. 1994).
Friedlander, "Macrophages are Sensitive to Anthrax Lethal Toxin . . . " J. Biol. Chem. 261(16):7123-7126 (Jun. 1986).
Arora et al., J. Bio. Chem., 267(22):15542-15548 (1992).
Arora et al. Abstract: Third Internatl. Sympos. on Immunotoxins, Orlando, FL (Jun. 19-21, 1992).
Quinn et al., J. Bio. Chem., 266(30):20124-20130 (1991).
Oeltmann and Frankel, News, 5:2334-2337 (Jul. 1991).
Singh et al., J. Bio. Chem., 266(23):15493-15497 (1991).
Singh et al., J. Bio. Chem., 264(32):19103-19107 (1989).
Leppla et al. Abstract: Fifth European Workshop on Bacterial Protein Toxins, Veldhoven (Jun. 30-Jul. 5, 1991).
Klimpel et al. Abstract: 1992 ASM General Meeting, New Orleans, LA (May 1992).
Novak, J.M., et al., "Functional Characterization of Protease-treated Bacillus anthracis Protective Antigen," J. of Biological Chemistry, 267(24):17186-17193 (Aug. 25, 1992).
Ivins, B.E., et al., "Cloning and Expression of the Bacillus anthracis Protective Antigen Gene in Bacillus subtilis," Infection and Immunity, 54(2):537-542 (Nov. 1986).
Molloy, S.S., et al, "Human Furin is a Calcium-dependent Serine Endoprotease That Recognizes the Sequence Arg-X-X-Arg and Efficiently Cleaves Anthrax Toxin Protective Antigen," J. of Biological Chemistry, 267(23):16396-16402 (Aug. 15, 1992).
Zhang, L., et al., "Inhibition of HIV-1 RNA Production by the Diphtheria Toxin-Related IL-2 Fusion Proteins DAB.sub.486 IL-2 and DAB.sub.389 IL-2," J. of Acquired Immune Deficiency Syndromes, 5(12):1181-1187 (1992).
O'Hare, M., et al., "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," FEBS Lett. 273(1,2):200-204 (Oct. 1990).
Williams, D.P., et al., "Cellular Processing of the Interleukin-2 Fusion Toxin DAB.sub.486 -IL-2 and Efficient Delivery of Diphtheria Fragment A to the Cytosol of Target Cells Requires Arg.sup.194," J. of Biological Chemistry, 265(33):20673-20677 (Nov. 25, 1990).
Ohishi, I., et al., "Visualizations of Binding and Internalization of Two Nonlinked Protein Components of Botulinum C.sub.2 Toxin in Tissue Culture Cells," Infection and Immunity, 60(11):4648-4655 (Nov. 1992).
Arora, Navene., et al. (1992) "Potent hybrid cytotoxins of anthrax lethal factor and the ADP-ribosylation domain of Pseudomonas exotoxin A are translocated direct to the cytosol of mammalian cells", Abstracts of the General Meeting of the American Society for Microbiology, abstract n. B-33.
Cataldi, Angel, et al. (1992) "Regulation of pag gene expression in Bacillus anthracis: Use of a pag-lacZ transcriptional fusion", FEMS Microbiology Letters, 98(1-3):89-94.
Klimpel, Kurt R., et al. (1992) "Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin", Proceedings of the National Academy of Sciences of USA, 89(21):10277-10281.
Arora, Navene, et al. (1993) "Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides", Journal of Biological Chemistry, 268(5):3334-3341.
Arora Naveen
Klimpel Kurt R.
Leppla Stephen H.
Nichols Peter J.
Singh Yogendra
Jagannathan Vasu S.
Romeo David S.
The Government of the United States as represented by the Secret
LandOfFree
Anthrax toxin fusion proteins and related methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anthrax toxin fusion proteins and related methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthrax toxin fusion proteins and related methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1555296